City of Hope, Duarte
University of California, Los Angeles (UCLA) - Medical Center, Los Angeles
University of California, San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center, San Francisco

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07226843

Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma

City of Hope Medical Center, Duarte
City of Hope Orange County Lennar Foundation Cancer Center, Irvine

Ap rekriteFaz 2

Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06453044

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

City of Hope, Duarte

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07101328

A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

Research Site, Clovis
Research Site, Los Alamitos
Research Site, San Diego
ak 1 plis

Ap rekriteFaz 3

Laj 18 a 130 · Tout sèks · Mizajou Sep 21, 2026 · NCT06549595

NEO100 and High-Grade Meningioma

University of Southern California, Los Angeles
Sutter Health Research Institute, San Francisco
Saint John Cancer Institute, Santa Monica

Ap rekriteFaz 2

Laj 12 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT05023018

Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

Research Site, Duarte

Ap rekriteFaz 2

Laj 18 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT06526793

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

David Geffen School of Medicine at UCLA, Los Angeles

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT06091254

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

City of Hope Comprehensive Cancer Center, Duarte
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
UC San Diego Moores Cancer Center, La Jolla
ak 2 plis

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT06860594

A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234

Research Site, Rialto

Ap rekriteFaz 1Volontè an sante akeyi

Laj 18 a 85 · Tout sèks · Mizajou Sep 1, 2026 · NCT07546760

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

University of California San Diego, La Jolla
University of California, Los Angeles, Los Angeles
Hoag Memorial Hospital Presbyterian, Newport Beach
ak 2 plis

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT05303519

A Study of ARC-02 in B-cell NHL

Start Cala, Los Angeles

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Aug 26, 2026 · NCT07691606

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

University of California-Irvine Medical Center, Irvine
Cedars-Sinai Medical Center, Los Angeles
University of California, Los Angeles (UCLA) Medical Center, Los Angeles
ak 1 plis

Ap rekriteFaz 1/2

Laj 18 ak plis · Tout sèks · Mizajou Aug 25, 2026 · NCT05826535

A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

David Geffen School of Medicine at UCLA, Los Angeles

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Aug 14, 2026 · NCT06149286

AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

Stanford University, Palo Alto

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Aug 12, 2026 · NCT06340737

Interventions in Mathematics and Cognitive Skills

Stanford Cognitive and Systems Neuroscience Laboratory, Palo Alto

Ap rekriteVolontè an sante akeyi

Laj 6 a 12 · Tout sèks · Mizajou Aug 11, 2026 · NCT05201534

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

City of Hope, Duarte
Valkyrie Clinical Trials, Los Angeles

Ap rekriteFaz 1/2

Laj 13 a 90 · Tout sèks · Mizajou Aug 6, 2026 · NCT06533579

STimulation to Activate RespIration

University of California San Diego, La Jolla

Ap rekrite

Laj 18 ak plis · Tout sèks · Mizajou Aug 6, 2026 · NCT06832306

A Study of APG-3288 in Relapsed/Refractory Blood Cancers

START Los Angele, Los Angeles

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Jul 30, 2026 · NCT07424833

This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma

City of Hope, Duarte

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Jul 24, 2026 · NCT07121946

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

City of Hope, Duarte
University of California, San Francisco, San Francisco

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Jul 2, 2026 · NCT05131022

Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

University of California Davis Comprehensive Cancer Center, Sacramento

Ap rekriteFaz 2

Laj 18 ak plis · Tout sèks · Mizajou Jun 29, 2026 · NCT04587687

Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma

City of Hope Medical Center, Duarte

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Jun 29, 2026 · NCT06815029

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

University of California, San Francisco, San Francisco

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Jun 22, 2026 · NCT04545762

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

City of Hope Comprehensive Cancer Center, Duarte
UCSF Helen Diller Medical Center at Parnassus Heights, San Francisco

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou May 20, 2026 · NCT06911502

Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

City of Hope Medical Center, Duarte

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Apr 20, 2026 · NCT06859008

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

City of Hope, Duarte
Los Angeles Cancer Network, Los Angeles
UCLA Medical Center of Hematology/Oncology, Los Angeles
ak 1 plis

Ap rekriteFaz 1/2

Laj 12 a 95 · Tout sèks · Mizajou Apr 15, 2026 · NCT04329728

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

City of Hope, Duarte

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Mar 20, 2026 · NCT04830137

Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy

Stanford, Stanford

Ap rekriteFaz 2

Laj 18 ak plis · Tout sèks · Mizajou Mar 13, 2026 · NCT06510361

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

UC Irvine Health, Orange

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Dec 10, 2025 · NCT05602363

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Massive Bio SYNERGY-AI site, Duarte
Massive Bio SYNERGY-AI site, Irvine
Massive Bio SYNERGY-AI site, La Jolla
ak 3 plis

Ap rekriteEtid obsèvasyon

Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774

Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy

Stanford Cancer Center, Palo Alto

Ap rekriteEtid obsèvasyon

Laj 18 ak plis · Tout sèks · Mizajou Aug 22, 2024 · NCT05255354

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.